Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Candel (CADL) stock fell 20% Tuesday after the company reported final overall survival data from a Phase 2 study of its drug ...